



## **Welcome to the NCCN 2024 Oncology Fellows Program**

NCCN would like to thank the outstanding faculty who are presenting and all of you for attending this educational program. We hope you find the information presented useful to your practice, and we encourage you to attend future NCCN educational initiatives.

<b>Agenda</b>	<b>Page 2</b>
<b>Accreditation Information</b>	<b>Pages 3 – 5</b>
<i>Supporting Organizations</i>	<i>Page 3</i>
<i>Claiming CE Credit</i>	<i>Page 5</i>
<b>Disclosure Information</b>	<b>Pages 6 – 8</b>
<b>Faculty Biographies</b>	<b>Pages 9 – 16</b>



## AGENDA

- 12:00 PM – 12:30 PM      **Lunch and Registration**
- 12:30 PM – 12:35 PM      **Opening Remarks**  
Wui-Jin Koh, MD  
Senior Vice President, Chief Medical Officer  
*National Comprehensive Cancer Network*
- 12:35 PM – 1:20 PM      **Health-Related Social Needs:  
How to Identify and Address the Needs of Your Patients**  
Eucharia Borden, MSW, LCSW, OSW-C, FAOSW  
Vice President of Programs and Health Equity, *Family Reach*
- 1:20 PM – 2:35 PM      **Health Insurance 101: Helping Patients Navigate the Health Insurance Maze**  
*MODERATOR:*      Randall A. Oyer, MD, *Penn Lancaster*  
*PANELISTS:*      Karen Costello, MSS, LSW, OSW-C  
*Cancer Support Community*  
Carmen E. Guerra, MD, MSCE  
*Abramson Cancer Center at the University of Pennsylvania*  
Heather Jones, PharmD, MS  
*Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer Center and  
Cleveland Clinic Taussig Cancer Institute*  
Bryan Loy, MD, MBA, *Humana*
- 2:35 PM – 3:50 PM      **Difficult Conversations: How to Communicate with Patients and Caregivers**  
Kavitha Ramchandran, MD  
*Stanford Cancer Institute*
- 3:50 PM – 4:05 PM      **Break**
- 4:05 PM – 5:05 PM      **Team-Based Management of Immunotherapy-Related Toxicities**  
Benjamin H. Kaffenberger, MD, MS  
*The Ohio State University Comprehensive Cancer Center –  
James Cancer Hospital and Solove Research Institute*  
Namrata Singh, MD, MSCI  
*University of Washington Medical Center*  
John A. Thompson, MD  
*Fred Hutchinson Cancer Center*
- 5:05 PM – 6:20 PM      **Preparing to Launch: What You Need to Know (But No One Ever Told You)  
About Entering the Oncology Workforce**  
*MODERATOR:*      Anthony J. Olszanski, MD, RPh  
*Fox Chase Cancer Center*  
*PANELISTS:*      Cynthia S. Anderson, MD  
*Baptist Health MD Anderson*  
Kimberley Lee, MD, MHS  
*Moffitt Cancer Center*  
John W. Sweetenham, MD  
*UT Southwestern Simmons Comprehensive Cancer Center*
- 6:20 PM – 6:25 PM      **Closing Remarks**
- 6:30 PM – 7:45 PM      **Networking Reception**





**Accreditation Information**

---

**PROGRAM OVERVIEW**

---

Designed specifically for oncology fellows, this ½-day, CE-certified program seeks to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the importance of communicating with patients and caregivers about difficult and sensitive topics, and preparing for entry into the oncology workforce.

---

**INTENDED AUDIENCE**

---

This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

---

**GOAL OF EDUCATION**

---

The goal of this activity is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

---

**GLOBAL LEARNING OBJECTIVES**

---

*Following this program, participants should be able to:*

- Evaluate advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to the following topics:
  - Health-Related Social Needs: How to Identify and Address the Needs of Your Patients;
  - Health Insurance 101: Helping Patients Navigate the Health Insurance Maze;
  - Difficult Conversations: How to Communicate with Patients and Caregivers;
  - Team-Based Management of Immunotherapy-Related Toxicities;
  - Preparing to Launch: What You Need to Know (But No One Ever Told You) about Entering the Oncology Workforce.

---

**CE SUPPORTERS**

---

Supported by educational grants from: AstraZeneca; BeiGene; Coherus BioSciences; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Supported by independent medical educational grants from Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; Regeneron Pharmaceuticals, Inc.

**ACCREDITATION STATEMENT***Joint Accreditation*

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

*Physicians*

NCCN designates this live activity for a maximum of 5.5 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**SESSION LEARNING OBJECTIVES**

*Following this program, participants should be able to:*

***Health-Related Social Needs: How to Identify and Address the Needs of Your Patients***

- Review the core measures of health-related social needs (HRSN).
- Discuss how and when to screen patients for HRSN, barriers to screening, and how to discuss HRSN with patients and caregivers.
- Describe the roles of other oncology care team members in addressing HRSN and the importance of educating patients and caregivers about these roles prior to referral.

***Health Insurance 101: Helping Patients Navigate the Health Insurance Maze***

- Describe different insurance types (e.g., Medicare, Medicaid, Affordable Care Act) and how coverage can affect patients with cancer and the treatment they receive.
- Discuss potential insurance-related barriers (e.g., uninsured, denial letters, high co-pays, deductibles) and how to address them.
- Identify advocacy organizations and members of the interprofessional oncology care team that help patients navigate health insurance issues.

***Difficult Conversations: How to Communicate with Patients and Caregivers***

- Explain the importance of having difficult conversations with patients and caregivers and how these types of conversations can impact patient care.
- Describe the differences between palliative, supportive and hospice care and how to communicate with patients and caregivers about them.
- Discuss resources that are available to patients and caregivers to help guide them in making difficult treatment decisions.

***Team-Based Management of Immunotherapy-Related Toxicities***

- Describe the different classes of immunotherapies used for cancer treatment.
- Recognize the toxicities that may occur with cancer immunotherapies.
- Discuss multidisciplinary strategies to facilitate early diagnosis and treatment of immunotherapy-related toxicities.

***Preparing to Launch: What You Need to Know (But No One Ever Told You)******About Entering the Oncology Workforce***

- Discuss how to align your passions and aspirations to discover your ideal career path.
- Incorporate practical skills that can be used to enhance career development and progression.
- Describe common obstacles and pitfalls that may be faced in early career.
- Explain key factors that will support a successful transition from fellow to attending physician.



## Accreditation Information

---

### NCCN ACCOUNT VERIFICATION

---

Before claiming credit, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Log in at [www.NCCN.org/login](http://www.NCCN.org/login).
  - If you do not have an NCCN account, click “**Create Account**” to register one for free.
2. Click “Profile” in the left side menu.
3. Verify that your **User Type** matches the type of credit you will claim (see list below).
4. Scroll down and click “**Save**” if you make any changes.

#### **User Types**

- Physician/Surgeon/Oncologist = *AMA PRA Category 1 Credits™*
- All other user types = certificate of participation

---

### HOW TO CLAIM CREDIT

---

To claim your credits, log in with the **same email address** you used to register for the program:

1. Log in at <http://education.nccn.org/fellows2024>
2. Click the ‘**Take Course**’ button.
3. Follow the prompts to complete the evaluation and claim your credits.

Upon successful completion, you will be able to view/print/download your certificate.

If you have any questions or need further assistance, please contact the NCCN Continuing Education Department at [education@nccn.org](mailto:education@nccn.org).



---

## **NCCN CONTINUING EDUCATION DISCLOSURE POLICY**

---

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

---

## **DEFINITIONS**

---

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

---

## **FACULTY DISCLAIMERS**

---

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.



**Disclosure Information**

---

**FACULTY, MODERATOR, AND PLANNER DISCLOSURES**

---

The faculty listed below have **no relevant** financial relationship(s) with ineligible companies to disclose.

**Cynthia S. Anderson, MD**  
**Karen Costello, MSS, LSW, OSW-C**  
**Deborah Freedman-Cass**  
**Heather Jones, PharmD, MS**  
**Karen Kanefield**  
**Wui-Jin Koh, MD**  
**Kimberley Lee, MD, MHS**  
**Bryan Loy, MD, MBA**  
**Randall A. Oyer, MD**  
**Kavitha Ramchandran, MD**  
**Carey Ramirez, ANP-C, ACHPN**  
**Namrata Singh, MD, MSCI**  
**John W. Sweetenham, MD**

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Eucharía Borden, MSW, LCSW, OSW-C, FAOSW**  
BeiGene: Honoraria

**Carmen E. Guerra, MD, MSCE**  
Genentech, Inc.: Grant/Research Support  
Guardant Health: Scientific Advisor

**Wenora Johnson**  
Flatiron Health, Inc.: Consulting Fee  
GSK: Honoraria  
Xilio Therapeutics: Honoraria

**Benjamin H. Kaffenberger, MD, MS**  
ADC Therapeutics: Consulting Fee  
Biogen Idec: Consulting Fee; Grant Research Support  
InflaRx: Grant/Research Support  
Merck & Co., Inc.: Grant/Research Support  
Novartis Pharmaceuticals Corporation: Consulting Fee

**Timothy Kubal, MD, MBA**  
Apellis Pharmaceuticals: Scientific Advisor



**Disclosure Information**

---

**FACULTY AND MODERATOR DISCLOSURES (CONTINUED)**

---

**Anthony J. Olszanski, MD, RPh**

Bristol Myers Squibb: Scientific Advisor  
InstilBio: Scientific Advisor  
Merck & Co., Inc.: Scientific advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Oncosec Immunotherapies: Scientific Advisor  
Pfizer Inc.: Honoraria  
Replimune: Scientific Advisor

**John A. Thompson, MD**

Alpine Immune Sciences: Equity Interest/Stock Options  
Mabquest SA: Scientific Advisor

---

**NCCN STAFF DISCLOSURES**

---

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Crystal Denlinger, MD, FACP**

2seventy bio: Grant/Research Support  
AbbVie, Inc.: Grant/Research Support  
Bluebird bio: Grant/Research Support  
Bristol Myers Squibb: Grant/Research Support  
Eli Lilly and Company: Grant/Research Support  
Genentech, Inc: Grant/Research Support  
GSK: Grant/Research Support  
Pfizer Inc: Grant/Research Support  
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.





---

**PROGRAM MODERATOR**

---

**Wui-Jin Koh, MD**, is the Senior Vice President/Chief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, he helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) program. In addition, he is responsible for medical leadership and oversight for NCCN's continuing medical education program and *JNCCN — Journal of the National Comprehensive Cancer Network* and represents the organization at clinical and scientific meetings. He is also actively involved in the NCCN Global initiatives.

Prior to joining NCCN in 2018, he served as Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency in radiation oncology and a clinical fellowship in metabolic tumor imaging. He is board-certified in radiation oncology.

Dr. Koh's research interests include combined chemo-radiation strategies, cancer management guidelines development, and the role of imaging in radiotherapy and cancer care. He specialized in the management of gynecologic and gastrointestinal tract tumors and the use of brachytherapy and intraoperative radiotherapy. He has received multiple Educator and National Top Doctors awards.

Dr. Koh is well-published and involved in numerous professional societies, including the Society of Gynecologic Oncology, the American Society of Clinical Oncology, the NRG-Oncology Clinical Trials Cooperative Group, the Western Association of Gynecologic Oncology, and the International Gynecologic Cancer Society.

---

**HEALTH-RELATED SOCIAL NEEDS: HOW TO IDENTIFY AND ADDRESS THE NEEDS OF YOUR PATIENTS**

---

**Eucharía Borden, MSW, LCSW, OSW-C, FAOSW**, is Vice President of Programs and Health Equity at Family Reach, a national organization dedicated to eradicating the financial barriers that accompany a cancer diagnosis.

In this role, Ms. Borden oversees the organization's program development and delivery. This includes the expansion of Family Reach's Cancer Equity Initiative, which focuses on meeting the needs of the most under-resourced and financially vulnerable populations in the cancer community. She is responsible for strategic growth, innovation, and program implementation to ensure Family Reach deepens and broadens its impact on families facing cancer nationwide.

In her previous role as Vice President of Health Equity at Cancer Support Community (CSC), Ms. Borden was responsible for ensuring that CSC headquarters' research, program, policy, and operations integrated relevant components of health equity, inclusion, and social determinants of health across all activities. Her steadfast commitment to ensuring all patients — regardless of race or socioeconomic status — have access to life-saving care has positioned her as a sought-after thought leader within the health care community.

Ms. Borden has earned national media attention for her work and expertise in this space, including a *Survivorship Today* interview with award-winning actor and advocate Sterling K. Brown and a leading spot in the "In Her Shoes" campaign hosted by Bristol Myers Squibb.

Ms. Borden has dedicated the last 17 years of her career to the oncology field, working in patient advocacy and direct social work practice within acute inpatient and outpatient hospital settings. She is a past-president of the Association of Oncology Social Work (AOSW) and a recognized AOSW Fellow. Ms. Borden also received the 2023 AOSW *Leadership in Oncology Social Work Award*, presented at the AOSW Annual Conference.



---

***HEALTH INSURANCE 101: HELPING PATIENTS NAVIGATE THE HEALTH INSURANCE MAZE***

---

**Karen Costello, MSS, LSW, OSW-C**, is the Senior Director Helpline, Lead Navigation Strategies at Cancer Support Community (CSC), a global nonprofit that uplifts and strengthens people impacted by cancer.

Ms. Costello completed her undergraduate studies at Rutgers University and earned her Master's of Social Work at Bryn Mawr College. She is certified by the Board of Oncology Social Work.

Ms. Costello is a mission-driven oncology care leader, bringing social work and navigation skills together with clinical operations expertise. She has 30 years of oncology experience as a social worker and practice administrator, having held positions at Fox Chase Cancer Center, the Leukemia & Lymphoma Society, and Penn Medicine at University of Pennsylvania Health. These roles spanned a variety of settings, including university health care, patient services, fundraising, and programs development in the non-profit cancer advocacy space.

At CSC, Ms. Costello is a member of the Programs Team and provides clinical oversight of the Cancer Support Helpline. Ms. Costello also coordinates navigation services for patients and caregivers. Her special areas of interest include financial navigation, addressing barriers to care, adult learning needs, and women's health concerns.

**Carmen E. Guerra, MD, MSCE**, is the Ruth C. and Raymond G. Perelman Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania.

Dr. Guerra is a practicing general internist and health equity researcher. At Penn, she also is the Vice Chair of Diversity and Inclusion for the Department of Medicine, and the Associate Director of Diversity and Outreach for the Abramson Cancer Center (ACC), where she also co-leads Community Outreach and Engagement.

Dr. Guerra's research focuses on eliminating barriers to cancer screening and clinical trials. Dr. Guerra serves on the American Cancer Society (ACS) Guideline Development Committee and has authored numerous articles, including the current ACS colorectal, cervical and lung cancer screening guidelines. These publications widely influence current clinical practice. In addition, she co-chaired the American Society of Clinical Oncology-Association of Community Cancer Centers (ASCO-ACCC) committee that developed and tested the first unconscious bias training for cancer researchers, "Just Ask," and the ASCO-ACCC Site Self Assessment for to enhance equity, diversity, and inclusion in cancer clinical trials.

Dr. Guerra is a member of the NCCN Diversity, Equity, and Inclusion Directors Forum served on the NCCN Elevating Cancer Equity Working Group.

---

**HEALTH INSURANCE 101: HELPING PATIENTS NAVIGATE THE HEALTH INSURANCE MAZE**

---

**Heather Jones, PharmD, MS**, is the Pharmacy Manager of Regional Oncology Services at Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Originally from Cleveland, Ohio, Dr. Jones earned her doctorate of pharmacy from Ohio Northern University and completed a residency in health-system pharmacy administration with a Master's degree in health system administration at UW Health.

Dr. Jones' clinical interests include revenue cycle management, oncology practice, legal affairs within the state and board of pharmacy, and regulatory compliance.

Dr. Jones previously held the position of Pharmacy Manager of Oncology Services at University of Wisconsin (UW) Health and served as an adjunct faculty member at the UW School of Pharmacy.

Professionally, Dr. Jones is Chair of the Professional Development Workforce Business Committee for Vizient and legal affairs representative for the Ohio Society for Health-System Pharmacy (OSHP). Dr. Jones also is a member of the American Society of Health-System Pharmacists (ASHP) and Educational Steering Committee for the Section of Pharmacy Practice Leaders. Additionally, Dr. Jones has been involved with NCCN for over 5 years; she is a member of the NCCN Pharmacy Directors Forum and serves on the NCCN Educational Programs Advisory Committee.

Outside of professional involvement, Dr. Jones is actively involved in LifeTeen ministries. Helping to support a ministry of over 150 teens in 9<sup>th</sup> through 12<sup>th</sup> grade is one of her most rewarding roles. Dr. Jones also supports giving back to the Rwandan community through the nonprofit organization Friends of Rwandan Education.

**Randall A. Oyer, MD**, is a practicing medical oncologist and holds several positions at Penn Medicine Lancaster General Health, including: Executive Medical Director of the Ann B. Barshinger Cancer Institute; Medical Director of Oncology; Medical Director of the Cancer Risk Evaluation Program; and Chairman of the Cancer Committee. Dr. Oyer also holds a faculty appointment as Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of Pennsylvania Perelman School of Medicine.

Dr. Oyer earned his medical degree from Georgetown University School of Medicine. He completed his residency and fellowship at Medical College of Pennsylvania. In his current practice, Dr. Oyer specializes in breast cancer immunotherapy, cancer genetics, and hereditary cancer risk.

Dr. Oyer is a member of several professional organizations, including the American College of Physicians, the American Society of Clinical Oncology, the Lancaster County Medical Society, and the Pennsylvania Society of Oncology & Hematology. He is Past-President of the Association of Community Cancer Centers (ACCC) and the founding chair of ACORI (ACCC Community Oncology Research Institute). He also is a member of the National Cancer Policy Forum at the National Academies of Science, Engineering, and Medicine. At Penn, Dr. Oyer serves on the Cancer Service Line Executive Committee and the Cancer Service Line Quality Committee at the Abramson Cancer Center.

Dr. Oyer is a member of the NCCN Educational Programs Advisory Committee.

---

**HEALTH INSURANCE 101: HELPING PATIENTS NAVIGATE THE HEALTH INSURANCE MAZE**

---

**Bryan Loy, MD, MBA**, is a Corporate Medical Director and serves as clinician lead for Oncology and Medical Specialty initiatives at Humana, a Medicare and Medicaid health plan.

Dr. Loy received his medical degree from the University of Louisville, where he also completed his residency and fellowship. He is board-certified in pathology (anatomic and clinical) and hematology.

Dr. Loy has served in clinical practice as well as industry. He has extensive experience in administrative roles, including as a Medical Director for a third-party administrator, Contract Medical Director for a Medicare A and Medicare B contractor, and a Laboratory Advisor for the Centers for Medicare and Medicaid Services. In his current role at Humana, his objectives remain to promote quality and value along with health plan support across the oncology and specialty medicine initiatives to improve the member experience and to reduce avoidable administrative burden.

Dr. Loy has served on a number of steering committees and advisory boards for professional oncology organizations, including the National Quality Forum, the American Cancer Society, and the National Business Group on Health.

Dr. Loy has participated as an expert panelist for NCCN Policy Summits and NCCN Academy for Excellence & Leadership in Oncology Programs.

---

**DIFFICULT CONVERSATIONS: HOW TO COMMUNICATE WITH PATIENTS AND CAREGIVERS**

---

**Kavitha Ramchandran, MD**, is a medical oncologist at Stanford Cancer Institute, specializing in palliative medicine and thoracic oncology. She holds a faculty appointment as Clinical Professor of Medicine in the Division of Oncology, where she also serves as the inaugural Chief of Mentoring and Career Development. Additionally, Dr. Ramchandran is the Medical Director of Cancer Care Services for Stanford Cancer Center across the enterprise.

Dr. Ramchandran completed medical school and residency training at University of California, San Francisco. She then completed her fellowship in medical oncology and palliative medicine at Northwestern University. Dr. Ramchandran is one of a few dually trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research and novel models of care.

Dr. Ramchandran's research focuses on innovative models of care delivery to understand how to integrate primary and specialist palliative care. She also does work in online education, patient-reported outcomes (PROs), and palliative care education, with the goal of scaling the education to be impactful and sustainable. In cancer care, Dr. Ramchandran does research on novel therapeutics in thoracic malignancies, including immunotherapy, new targeted agents, and new sequencing of approved drugs.

Dr. Ramchandran is recognized for her contributions as a leader in the research of thoracic malignancies, with a specific focus on thymic epithelial tumors. She serves as a principal investigator and sub-investigator on several research trials, from early phase to phase II and phase III studies. The goal of these trials is developing novel approaches and identifying new targets for the treatment of both thoracic malignancies and rare tumors, such as thymic epithelial tumors including thymoma and thymic cancers.

Dr. Ramchandran is a member of several professional organizations. She is a Fellow of the Center for Global Health at Stanford University and a faculty member for both Global Resource to Advance Cancer Education and Global Oncology. Additionally, she serves on the American Society of Clinical Oncology's Patient and Survivor Care Committee and the San Francisco General Hospital's Board for Cancer Awareness, Research, and Education.

Dr. Ramchandran is a member of the NCCN Older Adult Oncology Panel and the NCCN Palliative Care Panel. She also is a member of the NCCN Best Practice's Electronic Health Record PRO Workgroup.

---

**TEAM-BASED MANAGEMENT OF IMMUNOTHERAPY-RELATED TOXICITIES**

---

**Benjamin Kaffenberger, MD, MS**, is a practicing dermatologist and Clinical Associate Professor of Dermatology at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James). He also is the cancer center's Director of Inpatient Consultation Services and Teledermatology Outreach.

Dr. Kaffenberger received his medical degree from the Ohio State University College of Medicine and completed his internship and residency at the Ohio State University Wexner Medical Center. He is certified by the American Board of Dermatology.

Dr. Kaffenberger specializes in hospital dermatology and works with individuals diagnosed with complex medical diseases, drug and allergic reactions, and autoimmune skin diseases. His clinical interests include Stevens-Johnson syndrome, drug and allergy hypersensitivity syndromes, pyoderma gangrenosum and ulcerating skin conditions, vasculitis, and hidradenitis suppurativa.

In addition to his clinical work, Dr. Kaffenberger is member of the Translational Therapeutics Program at the OSUCCC - James, where his research focuses on the early identification, description, and treatment of novel cutaneous toxicities from targeted anticancer therapies. His other research interests include cutaneous graft-versus-host disease, teledermatology and automated assessments, biobanking cancer and non-cancer skin tissue, and conducting clinical trials to develop new therapeutics.

Dr. Kaffenberger is a member of several professional organizations, including the Ohio Dermatology Association, the Medical Dermatology Society, the Society of Dermatology Hospitalists, and the Association of Professors of Dermatology. His work has been published in top peer-reviewed dermatology journals, and he is a past-recipient of a several awards for leadership, teaching, clinical and service excellence, and patient satisfaction.

Dr. Kaffenberger serves as a member and dermatology representative on the NCCN Management of Immunotherapy-Related Toxicity Panel.

**Namrata Singh, MD, MSCI**, is an Assistant Professor of Medicine in the Division of Rheumatology and an Adjunct Assistant Professor of Epidemiology at the University of Washington. She also leads the Rheumatology Immune-Related Adverse Events Clinic at the University of Washington Medical Center (UWMC) and is a member of the Fred Hutchinson Cancer Center.

Dr. Singh received her medical degree from All India Institute of Medical Sciences in New Delhi, India. She completed her residency at Mount Sinai Medical Center, followed by a fellowship in adult rheumatology at Temple University. She also has a Master's in Clinical Investigation from the University of Iowa.

In addition to her role as a clinician, Dr. Singh serves as educator for residents and fellows at UWMC. She also is an active clinical researcher and spends her time conducting innovative studies to build an evidence base for the care of patients with rheumatic diseases and cancer. Her current work is supported by a *K23 Mentored Patient-Oriented Research Career Development Award* from the National Institutes of Health to pursue studies on this topic.

In addition to conducting cancer and pharmacoepidemiologic studies using large databases, Dr. Singh's research interests include COVID-19, pregnancy outcomes among women with rheumatic diseases, and aging research -- especially measuring frailty in rheumatoid arthritis.

---

**TEAM-BASED MANAGEMENT OF IMMUNOTHERAPY-RELATED TOXICITIES**

---

**John A. Thompson, MD**, is Medical Director of the Phase I Clinical Trials Program for Solid Tumors at the Fred Hutchinson Cancer Center. He also is a Professor in the Medical Oncology Division at the University of Washington School of Medicine and a member of the Clinical Research Division at Fred Hutchinson Cancer Center.

Dr. Thompson received his medical degree from the University of Alabama at Birmingham. He completed an internship and residency in internal medicine and a fellowship in oncology at the University of Washington.

Dr. Thompson has devoted his career to developing better ways to treat kidney cancer and melanoma. His clinical research efforts focus on novel therapies such as cancer immunotherapy, specially activated lymphocytes and cytokines, and the use of blood stem cell transplants. Alongside researchers in the Phase I Clinical Trials Program, Dr. Thompson works with local biotechnology and pharmaceutical firms to develop novel therapies for patients with solid tumor cancers. His goal is to speed the translation of the most promising experimental approaches into clinically useful therapies that can improve the lives of thousands of patients each year.

Dr. Thompson is a member of several professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer, and the National Kidney Cancer Association. He has authored or co-authored more than 200 articles, which have appeared in *publications such as Journal of Immunology, Blood, Journal of Clinical Oncology, Clinical Cancer Research, and the Journal of National Comprehensive Cancer Center (JNCCN)*.

Dr. Thompson is Chair of the NCCN Management of Immunotherapy-Related Toxicity Panel. He also has served on several committees and advisory boards for the NCCN Oncology Research Program.

---

**PREPARING TO LAUNCH:****WHAT YOU NEED TO KNOW (BUT NO ONE EVER TOLD YOU) ABOUT ENTERING THE ONCOLOGY WORKFORCE**

---

**Cynthia S. Anderson, MD**, is a radiation oncologist at Baptist Health MD Anderson in Jacksonville, Florida, where she also serves as the Physician Co-Lead of Diversity, Equity, and Inclusivity (DEI). Dr. Anderson also holds a faculty appointment as an Adjunct Associate Professor at The University of Texas MD Anderson Cancer Center (MDACC).

Dr. Anderson received her medical degree and completed her internship and residency at Emory University, during which time she served as the Chief Resident for her program. She is certified by the American Board of Radiology.

Dr. Anderson has a longstanding passion for providing care to patients with cancer. Her areas of expertise include breast, melanoma, and musculoskeletal cancers. She continues to do research, publish, and serve her community both in and out of medicine. She treats patients of all ages, supporting their cancer journey and education on diagnosis and treatment options.

Dr. Anderson is a member of several professional organizations. She is a graduate of the American Society of Clinical Oncology's (ASCO) Leadership Development Program and has served on the ASCO and ASTRO Boards. She also is a member of the Duval County Medical Society and the Florida Medical Association. In addition to being the Physician Co-Lead for DEI for her hospital system, Dr. Anderson serves as the Cancer Network Research Liaison for Radiation Oncology for MDACC. She also co-founded the Pink Ribbon Symposium, a breast cancer non-profit educational group.

---

**PREPARING TO LAUNCH:  
WHAT YOU NEED TO KNOW (BUT NO ONE EVER TOLD YOU) ABOUT ENTERING THE ONCOLOGY WORKFORCE**

---

**Kimberley Lee, MD, MHS**, is an Assistant Member in the Department of Breast Oncology at Moffitt Cancer Center.

Dr. Lee received her medical degree from the Johns Hopkins University School of Medicine and her Master's of Health Sciences in general epidemiology from The Johns Hopkins University Bloomberg School of Public Health. She completed an internal medicine residency at Johns Hopkins Bayview Medical Center and a medical oncology fellowship at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Dr. Lee's research expertise involves using the tools of epidemiology, health services research, and implementation science to investigate modifiable biological, clinical, and health care related factors that contribute to disparities in breast cancer survival. She is particularly interested in developing interventions to address these factors and improve survival for women with breast cancer. She has experience in analyzing large databases to better understand disparities in care and performs qualitative work to understand patient and provider factors that impact breast cancer care.

Dr. Lee is a past-recipient of the NCCN Foundation's Young Investigator's Award Program. She currently serves on the NCCN Survivorship Panel.

**Anthony J. Olszanski, MD, RPh**, is Associate Professor and Vice Chair of Clinical Research at Fox Chase Cancer Center, Director of the Early Clinical Drug Development Phase I Program, and Co-Director of the Melanoma and Skin Cancer Program.

Dr. Olszanski completed his hematology and oncology fellowship and clinical pharmacology fellowship at Dartmouth-Hitchcock Medical Center. He is board-certified in internal medicine, medical oncology, and clinical pharmacology. He focuses on the treatment of lung cancer and cutaneous malignancies with a focus on melanoma.

Dr. Olszanski serves as a mentor to numerous oncology fellows, internal medicine residents, and colleagues. In addition to attracting a large number of sponsored Phase I trials, he has written, developed, and run (or served as a sub-investigator on) many investigator-initiated trials. Dr. Olszanski has served as the Principal Investigator on more than 50 trials.

Dr. Olszanski is a member of the NCCN Melanoma Panel, the NCCN Management of Immunotherapy-Related Toxicity Panel, and the NCCN Oncology Research Program Investigator Steering Committee. He also serves as an Associate Editor for *JNCCN—Journal of the National Comprehensive Cancer Network* and as a COTT Consultant for the NCCN Chemotherapy Order Templates (NCCN Templates®) Committee.



***PREPARING TO LAUNCH:***

***WHAT YOU NEED TO KNOW (BUT NO ONE EVER TOLD YOU) ABOUT ENTERING THE ONCOLOGY WORKFORCE***

**John W. Sweetenham, MD**, is a Adjunct Professor of Medicine at UT Southwestern Simmons Comprehensive Cancer Center.

Dr. Sweetenham earned his medical degree at Saint Bartholomew's Hospital Medical College in London. He completed a residency at the Royal United Hospital in Bath and received advanced training in medical oncology through a fellowship at the University of Southampton, where he then served as a faculty member and leader of the lymphoma and transplant programs. He also completed a visiting fellowship in tumor immunology at Harvard Medical School and the Dana-Farber Cancer Institute.

Prior to joining the UT Southwestern faculty in 2019, Dr. Sweetenham was Senior Director for Clinical Affairs and Physician in Chief at the Huntsman Cancer Institute of the University of Utah, where he led strategic planning efforts for the clinical cancer service line and introduced innovative cancer care delivery models.

Dr. Sweetenham is internationally renowned for his clinical research in malignant lymphomas and the use of stem cell transplantation. He has authored more than 200 original articles, chapters, and books in this area of investigation.

Dr. Sweetenham is a Fellow of the American College of Physicians, the American Society of Clinical Oncology (ASCO), and the Royal College of Physicians, UK. He also is a member of the American Society of Hematology (ASH). He previously served on the Lymphoma Working Committee of the Eastern Cooperative Oncology Group (ECOG) and the Lymphoma Working Group of SWOG. He also previously served as Chair of the Clinical Trials Committee of Leukemia and Lymphoma Research in the UK.

Dr. Sweetenham is Chair of the NCCN Board of Directors and serves on the Board's Executive and Governance Committees. Dr. Sweetenham also is a member of the NCCN Policy Advisory Group and the NCCN COVID-19 Vaccination Advisory Committee.